|
1
|
Rastrelli M, Tropea S, Rossi CR and
Alaibac M: Melanoma: epidemiology, risk factors, pathogenesis,
diagnosis and classification. In Vivo. 28:1005–1011.
2014.PubMed/NCBI
|
|
2
|
Minini R, Rohrmann S, Braun R, Korol D and
Dehler S: Incidence trends and clinical-pathological
characteristics of invasive cutaneous melanoma from 1980 to 2010 in
the Canton of Zurich, Switzerland. Melanoma Res. 27:145–151. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin AY, Wang PF, Li H and Kolker JA:
Multicohort model for prevalence estimation of advanced malignant
melanoma in the USA: An increasing public health concern. Melanoma
Res. 22:454–459. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Read T, Webber S, Thomas J, Wagels M,
Schaider H, Soyer HP and Smithers BM: Protocol for the TIDAL
melanoma study: Topical imiquimod or diphenylcyclopropenone for the
management of cutaneous in-transit melanoma metastases-a phase II,
single centre, randomised, pilot study. BMJ Open. 7:e0168162017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pike E, Hamidi V, Saeterdal I,
Odgaard-Jensen J and Klemp M: Multiple treatment comparison of
seven new drugs for patients with advanced malignant melanoma: A
systematic review and health economic decision model in a Norwegian
setting. BMJ Open. 7:e0148802017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen J, Lei QQ, Chen X, Cao C and Cen Y:
Diagnostic performance of micropthalmia transcription factor for
melanoma: A systematic review and meta-analysis. Eur Rev Med
Pharmacol Sci. 18:798–805. 2014.PubMed/NCBI
|
|
7
|
Sun J, Zager JS and Eroglu Z:
Encorafenib/binimetinib for the treatment of BRAF-mutant advanced,
unresectable, or metastatic melanoma: Design, development, and
potential place in therapy. OncoTargets Ther. 11:9081–9089. 2018.
View Article : Google Scholar
|
|
8
|
Cosgarea I, Ritter C, Becker JC,
Schadendorf D and Ugurel S: Update on the clinical use of kinase
inhibitors in melanoma. J Dtsch Dermatol Ges. 15:887–893. 2017.
View Article : Google Scholar
|
|
9
|
Robsahm TE, Helsing P, Nilssen Y, Vos L,
Rizvi SMH, Akslen LA and Veierød MB: High mortality due to
cutaneous melanoma in Norway: A study of prognostic factors in a
nationwide cancer registry. Clin Epidemiol. 10:537–548. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boniol M, Autier P and Gandini S: Melanoma
mortality following skin cancer screening in Germany. BMJ Open.
5:e0081582015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bottoni U, Paolino G, Didona D, Corsetti
P, Clerico R, Cantisani C, Richetta AG, Arcidiacono V, Scali E and
Pranteda G: Improvement of survival in patients with melanoma and
non-melanoma skin cancers compared to patients without double
cutaneous malignancies. Eur Rev Med Pharmacol Sci. 19:1640–1644.
2015.PubMed/NCBI
|
|
12
|
Filitis DC, Rauh J and Mahalingam M: The
HGF-cMET signaling pathway in conferring stromal-induced
BRAF-inhibitor resistance in melanoma. Melanoma Res. 25:470–478.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mak G, Arkenau HT and Chin M: Resistance
surveillance in a BRAF mutant melanoma patient on long-term
BRAF-inhibitor treatment. Melanoma Res. 24:408–412. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cohen-Solal KA, Kaufman HL and Lasfar A:
Transcription factors as critical players in melanoma invasiveness,
drug resistance, and opportunities for therapeutic drug
development. Pigment Cell Melanoma Res. 31:241–252. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gladfelter P, Darwish NHE and Mousa SA:
Current status and future direction in the management of malignant
melanoma. Melanoma Res. 27:403–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Najem A, Krayem M, Perdrix A, Kerger J,
Awada A, Journe F and Ghanem G: New drug combination strategies in
melanoma: Current status and future directions. Anticancer Res.
37:5941–5953. 2017.PubMed/NCBI
|
|
17
|
Zhu Z, Liu W and Gotlieb V: The rapidly
evolving therapies for advanced melanoma - Towards immunotherapy,
molecular targeted therapy, and beyond. Crit Rev Oncol Hematol.
99:91–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bogusławska J and Małecki M: siRNA
preparations in gene therapy of melanoma. Med Wieku Rozwoj.
17:196–201. 2013.PubMed/NCBI
|
|
19
|
Rajendran V, Kalita P, Shukla H, Kumar A
and Tripathi T: Aminoacyl-tRNA synthetases: Structure, function,
and drug discovery. Int J Biol Macromol. 111:400–414. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SW, Cho BH, Park SG and Kim S:
Aminoacyl-tRNA synthetase complexes: Beyond translation. J Cell
Sci. 117:3725–3734. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jabbour S and Harissi-Dagher M: Recessive
mutation in a nuclear-encoded mitochondrial tRNA synthetase
associated with infantile cataract, congenital neurotrophic
keratitis, and orbital myopathy. Cornea. 35:894–896. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwartzentruber J, Buhas D, Majewski J,
Sasarman F, Papillon-Cavanagh S, Thiffault I, Sheldon KM,
Massicotte C, Patry L, Simon M, et al FORGE Canada Consortium, :
Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA
synthetase IARS2 in patients with cataracts, growth hormone
deficiency with short stature, partial sensorineural deafness, and
peripheral neuropathy or with Leigh syndrome. Hum Mutat.
35:1285–1289. 2014.PubMed/NCBI
|
|
23
|
Zhong L, Zhang Y, Yang JY, Xiong LF, Shen
T, Sa YL, O'Yang YM, Zhao SH and Chen JY: Expression of IARS2 gene
in colon cancer and effect of its knockdown on biological behavior
of RKO cells. Int J Clin Exp Pathol. 8:12151–12159. 2015.PubMed/NCBI
|
|
24
|
Miyaki M, Iijima T, Shiba K, Aki T, Kita
Y, Yasuno M, Mori T, Kuroki T and Iwama T: Alterations of repeated
sequences in 5′ upstream and coding regions in colorectal tumors
from patients with hereditary nonpolyposis colorectal cancer and
Turcot syndrome. Oncogene. 20:5215–5218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin J, Liu W, Li R, Liu J, Zhang Y, Tang W
and Wang K: IARS2 silencing induces non-small cell lung cancer
cells proliferation inhibition, cell cycle arrest and promotes cell
apoptosis. Neoplasma. 63:64–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang Z, Wang X, Yan Q, Zhang S and Li Y:
Knockdown of IARS2 suppressed growth of gastric cancer cells by
regulating the phosphorylation of cell cycle-related proteins. Mol
Cell Biochem. 443:93–100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Tian Y, Li X, Wang B, Zhai D, Bai Y,
Dong C and Chao X: Knockdown of IARS2 inhibited proliferation of
acute myeloid leukemia cells by regulating p53/p21/PCNA/eIF4E
pathway. Oncol Res. 27:673–680. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lois C, Hong EJ, Pease S, Brown EJ and
Baltimore D: Germline transmission and tissue-specific expression
of transgenes delivered by lentiviral vectors. Science.
295:868–872. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garbe C, Peris K, Hauschild A, Saiag P,
Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J,
Stratigos AJ, et al European Dermatology Forum (EDF); European
Association of Dermato-Oncology (EADO); European Organisation for
Research and Treatment of Cancer (EORTC), : Diagnosis and treatment
of melanoma. European consensus-based interdisciplinary guideline -
Update 2016. Eur J Cancer. 63:201–217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tas F: Metastatic behavior in melanoma:
Timing, pattern, survival, and influencing factors. J Oncol.
2012:6476842012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sarkar D, Leung EY, Baguley BC, Finlay GJ
and Askarian-Amiri ME: Epigenetic regulation in human melanoma:
Past and future. Epigenetics. 10:103–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Diodato D, Ghezzi D and Tiranti V: The
mitochondrial aminoacyl tRNA synthetases: Genes and syndromes. Int
J Cell Biol. 2014:7879562014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Antonellis A, Ellsworth RE, Sambuughin N,
Puls I, Abel A, Lee-Lin SQ, Jordanova A, Kremensky I, Christodoulou
K, Middleton LT, et al: Glycyl tRNA synthetase mutations in
Charcot-Marie-tooth disease type 2D and distal spinal muscular
atrophy type V. Am J Hum Genet. 72:1293–1299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao P and Fox PL: Aminoacyl-tRNA
synthetases in medicine and disease. EMBO Mol Med. 5:332–343. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ko YG, Kim EY, Kim T, Park H, Park HS,
Choi EJ and Kim S: Glutamine-dependent antiapoptotic interaction of
human glutaminyl-tRNA synthetase with apoptosis signal-regulating
kinase 1. J Biol Chem. 276:6030–6036. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim S, You S and Hwang D: Aminoacyl-tRNA
synthetases and tumorigenesis: More than housekeeping. Nat Rev
Cancer. 11:708–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perli E, Giordano C, Tuppen HA, Montopoli
M, Montanari A, Orlandi M, Pisano A, Catanzaro D, Caparrotta L,
Musumeci B, et al: Isoleucyl-tRNA synthetase levels modulate the
penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile)
mutation causing hypertrophic cardiomyopathy. Hum Mol Genet.
21:85–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fattore L, Costantini S, Malpicci D,
Ruggiero CF, Ascierto PA, Croce CM, Mancini R and Ciliberto G:
MicroRNAs in melanoma development and resistance to target therapy.
Oncotarget. 8:22262–22278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bennett PE, Bemis L, Norris DA and
Shellman YG: miR in melanoma development: miRNAs and acquired
hallmarks of cancer in melanoma. Physiol Genomics. 45:1049–1059.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gonzalez H, Lema C, Kirken RA, Maldonado
RA, Varela-Ramirez A and Aguilera RJ: Arsenic-exposed keratinocytes
exhibit differential microRNAs expression profile; Potential
implication of miR-21, miR-200a and miR-141 in melanoma pathway.
Clin Cancer Drugs. 2:138–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim YK and Kim VN: Processing of intronic
microRNAs. EMBO J. 26:775–783. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lei H, Li H, Xie H, Du C, Xia Y and Tang
W: Role of MiR-215 in Hirschsprung's Disease pathogenesis by
targeting SIGLEC-8. Cell Physiol Biochem. 40:1646–1655. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li N, Zhang QY, Zou JL, Li ZW, Tian TT,
Dong B, Liu XJ, Ge S, Zhu Y, Gao J, et al: miR-215 promotes
malignant progression of gastric cancer by targeting RUNX1.
Oncotarget. 7:4817–4828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gao X, Cai Y and An R: miR 215 promotes
epithelial to mesenchymal transition and proliferation by
regulating LEFTY2 in endometrial cancer. Int J Mol Med.
42:1229–1236. 2018.PubMed/NCBI
|
|
47
|
Wei Y, Sun J and Li X: MicroRNA-215
enhances invasion and migration by targeting retinoblastoma tumor
suppressor gene 1 in high-grade glioma. Biotechnol Lett.
39:197–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
